Scholar Rock Holding Corporation

NasdaqGS:SRRK Stock Report

Market Cap: US$5.8b

Scholar Rock Holding Management

Management criteria checks 1/4

Scholar Rock Holding's CEO is David Hallal, appointed in Apr 2025, has a tenure of 1.08 years. total yearly compensation is $33.30M, comprised of 1.9% salary and 98.1% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $19.42M. The average tenure of the management team and the board of directors is 1.8 years and 10.7 years respectively.

Key information

David Hallal

Chief executive officer

US$33.3m

Total compensation

CEO salary percentage1.91%
CEO tenure1.1yrs
CEO ownership0.3%
Management average tenure1.8yrs
Board average tenure10.7yrs

Recent management updates

Recent updates

New Narrative • Mar 07

Muscle-Targeted SMA Therapies And Global Expansion Will Reshape Long-Term Outlook

Catalysts About Scholar Rock Holding Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • Jan 06

Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating

Summary I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not clinical, with no new efficacy or safety concerns; remediation and a second CDMO are underway. Topline phase 3 data support apitegromab's novel mechanism and broad label potential, materially expanding SRRK's addressable market and pricing power. SRRK's risks include potential further manufacturing delays, regulatory timing uncertainties, and possible capital raises if approval is postponed beyond the 2027 cash runway. Read the full article on Seeking Alpha
Seeking Alpha • Apr 17

Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade

Summary Scholar Rock Holding Corporation's lead candidate, apitegromab, has shown promising efficacy in treating SMA and is awaiting FDA and EMA approval, with a potential market launch by late 2025. Apitegromab could achieve blockbuster status with peak revenue potential >$2.5bn, especially based on its ability to build muscle mass in combo with gene therapies like Spinraza and Zolgensma. Scholar Rock's obesity therapy potential with apitegromab and GLP-1 RA combo presents a high-risk, high-reward scenario, with significant upside if Phase 2 data is positive. Despite financial challenges and potential dilution, I upgrade SRRK stock to a "Buy" due to its promising pipeline and undervalued stock price at $30. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Summary Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders. The global obesity drugs market is expected to reach $200 billion by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Dec 24

Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High

Summary Scholar Rock's lead candidate, apitegromab, showed promising Phase 3 results in SMA, boosting shares by over 325%, with plans for regulatory submissions in the US and EU. Despite positive data, Scholar Rock faces financial challenges, including significant net losses and limited cash, suggesting potential future fundraisings. The company is exploring apitegromab's potential in obesity treatment, with a Phase 2 study underway, in combo with a GLP-1 agonist drug - results are expected in Q2 2025. Given current valuation and financial risks, I recommend a "Hold" rating, with potential buying opportunities post-approval or pre-obesity study results if the share price dips below $30, I'd suggest. Read the full article on Seeking Alpha
Seeking Alpha • Oct 07

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Summary Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst. The spinal muscular atrophy market in the 7 major markets [7MM] is expected to reach $13 billion by 2034. Read the full article on Seeking Alpha
Seeking Alpha • Jan 12

Scholar Rock: Solid Data And Good Prospects

Summary Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has David Hallal's remuneration changed compared to Scholar Rock Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$409m

Dec 31 2025US$33mUS$638k

-US$378m

Sep 30 2025n/an/a

-US$353m

Jun 30 2025n/an/a

-US$316m

Mar 31 2025n/an/a

-US$264m

Dec 31 2024US$401kn/a

-US$246m

Sep 30 2024n/an/a

-US$226m

Jun 30 2024n/an/a

-US$204m

Mar 31 2024n/an/a

-US$183m

Dec 31 2023US$417kn/a

-US$166m

Sep 30 2023n/an/a

-US$159m

Jun 30 2023n/an/a

-US$160m

Mar 31 2023n/an/a

-US$166m

Dec 31 2022US$316kn/a

-US$135m

Sep 30 2022n/an/a

-US$131m

Jun 30 2022n/an/a

-US$125m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021US$315kn/a

-US$132m

Sep 30 2021n/an/a

-US$122m

Jun 30 2021n/an/a

-US$109m

Mar 31 2021n/an/a

-US$97m

Dec 31 2020US$400kn/a

-US$86m

Sep 30 2020n/an/a

-US$71m

Jun 30 2020n/an/a

-US$64m

Mar 31 2020n/an/a

-US$57m

Dec 31 2019US$303kn/a

-US$51m

Compensation vs Market: David's total compensation ($USD33.30M) is above average for companies of similar size in the US market ($USD8.38M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Hallal (59 yo)

1.1yrs
Tenure
US$33,300,927
Compensation

Mr. David L. Hallal is Chief Executive Officer of Scholar Rock, Inc. since April 27, 2025 and serves as its Chairman of the Board of Directors since July 2017. He had been its Executive Chairman since Apri...

Leadership Team

NamePositionTenureCompensationOwnership
David Hallal
CEO & Chairman of the Board1.1yrsUS$33.30m0.34%
$ 19.4m
Vikas Sinha
CFO & Treasurer1.1yrsUS$13.12m0.040%
$ 2.3m
Robert Woods
Chief Operating Officer1.1yrsUS$13.16m0.040%
$ 2.3m
Akshay Vaishnaw
President of R&D1.1yrsUS$14.89m0.049%
$ 2.8m
Erin Moore
Interim Principal Financial & Accounting Officer6.6yrsno data0.069%
$ 4.0m
Lisa Wyman
Chief Technical & Quality Officer1.3yrsno datano data
Mo Qatanani
Chief Scientific Officer2.3yrsUS$2.96m0%
$ 0
Rushmie Nofsinger
Vice President of Corporate Affairs & Investor Relationsno datano datano data
Junlin Ho
General Counsel & Corporate Secretary6.2yrsUS$2.13m0.11%
$ 6.3m
Caryn Parlavecchio
Chief Human Resources Officer4.8yrsno data0.072%
$ 4.2m
Lisa Price
Senior Vice President of Human Resourcesno datano datano data
Ryan Iarrobino
Senior Vice President of Clinical Development & Operations6.2yrsno datano data
1.8yrs
Average Tenure
53yo
Average Age

Experienced Management: SRRK's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
David Hallal
CEO & Chairman of the Board8.8yrsUS$33.30m0.34%
$ 19.4m
Akshay Vaishnaw
President of R&D12.3yrsUS$14.89m0.049%
$ 2.8m
Michael Gilman
Independent Director & Member of Scientific Advisory Board12.5yrsUS$531.05k0.040%
$ 2.3m
Timothy Springer
Member of Scientific Advisory Boardno dataUS$48.97kno data
Jeffrey Flier
Independent Director & Member of Scientific Advisory Board9.6yrsUS$540.66k0.014%
$ 791.3k
Leonard Zon
Member of Scientific Advisory Boardno datano datano data
Daniel Rifkin
Member of Scientific Advisory Boardno datano datano data
Kristina Burow
Independent Director11.8yrsUS$531.05k0.086%
$ 5.0m
Joan Massague
Member of Scientific Advisory Boardno datano datano data
Scott L. Friedman
Member of Scientific Advisory Boardno datano datano data
Barry Coller
Member of Scientific Advisory Boardno datano datano data
Joshua Reed
Independent Director5.2yrsUS$540.05k0.0068%
$ 389.9k
10.7yrs
Average Tenure
66yo
Average Age

Experienced Board: SRRK's board of directors are seasoned and experienced ( 10.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 17:18
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scholar Rock Holding Corporation is covered by 24 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Etzer DaroutBarclays
Evan SeigermanBMO Capital Markets Equity Research